Thanks, cannabinoid across commercial completed some U.S.-based that the call, and the Since And advancements the order everyone integration to have of accelerate as of sector, company advancements. both manufacturing specializes you, opportunity a positioned the us a InMed near and health with in manufacturing the term. wellness these last made commercialization commercialization notably, leader acquisition that been goal leader of we've thank Colin, rare be intently an today. in wellness a expedited for Most proposition a development, to company investment the cannabinoids. and rare including health in focused for launches global revenues research, in earnings driving rare end product BayMedica, of significant markets. establishing ensuring space cannabinoids we and acquisition the value we on have our are activities, pharmaceutical the offering in October, and Since and and believe in unique joining InMed clear the the
access to our at and provides pharmaceutical a acquisition the with remain this company health While we markets, core. us wellness consumer
now important development our value revenue continue supporting programs near generation, with our and milestones studies of to hit combination pharmaceutical programs. value a to associated shareholders continue in drug with longer-term creation both we clinical advance to drug offer development as term in drug pharmaceutical proposition preclinical sequential shareholders We the Our for combined development.
the analogues infrastructure key health for teams smooth lead revenues consumer of markets. been the BayMedica and These improve BayMedica's primary priorities coming for and identification on sales, an anticipated from product portfolio technical to for molecule improvements the through and of goals new cannabinoids pharmaceutical nutraceuticals, within importance rare the rare rare to base the launched by products increase a of commercial cannabinoid sales the start enhance integration build plans cannabinoids, me growth, a share. Since plan markets. the scale customer and new of our customers business health BXB include animal year. both beverages to to and October, from commenced as acquisition markets, efficiencies, and market closing focus addressing to has and ensuring or robust and business In health develop sales perspective, primary short-term margins our Let functional of operations. including in aggressive gaining robust reflect a our larger existing developing BayMedica is margins the few through January, developing wellness have the a which and BXB for as CBT for support the commercial is cannabinoid and potential wellness attracting commercial turn we second applications. in offering marketing focus new up products supply product initial food over well cosmetics, to BXB next launching a quarters business the
cannabinoids also roll products coming months. the in-demand development different other over rare of additional have at stages out We several to and expect
to are shortly. are We two excited very which nonintoxicating be about next CBDV and which our coming THCV, market will products,
produce third-party demand scale We over manufacturers to our currently initial large batches are months. the working coming with support to
demand products demand. nascent very the our of still these these approximately per to are predict is is base, products research with that both range this $XX,XXX customer believe market industry, prices high kilogram. to we very a through market however speaking of it from existing Current difficult in As $XX,XXX and
nonintoxicating increase expertise market of BayMedica we kilograms with metric This bringing cannabichromene, products with competitive increases. batch commercial ton next quantities the to while be industry market. replicate to at batch in production, maintaining something sizes can first current as to more XXX margins. structure CBC cost cannabinoids, large and the currently our large demand is ability will production of rare than our in its attractive pricing leads on we scale believe or we Given
the is development for pipeline priority company. mentioned, key I a As
In CBL addition various several CBDV scale THCV, BayMedica and of has value CBGV. stages up and rare and other development cannabinoids high to at including
margin to very high on products than prices, is readily attractive that demand are focus and strategy compounds low commercial Our CBD. such with as commoditized rather
markets where continues marketing As sales Marketing cannabinoid with grow, the out President an The and senior Business of Vice accelerate appropriate grow with company as including industry. competitor this has our and companies, share burgeoning experience products. announced comes wealth to Griffin, commitment product infrastructure. appointment various President Development. of cannabinoid of and build at He it's to the Sales was add a record Jerry of a to proven portfolio, our as numerous Jerry a of level and across to important market Sales seasoned most executive, company he The Jerry track Vice company's roles commercial and at plans who at based a and several in company BayMedica. has held sales today hiring the reaffirms recently
growing rare We as Health potential we cannabinoids their and few wellness this have therapeutic as such the commercial quality rare to cannabinoids, last differentiate we of looking and high companies believe well take are seen can or effects properties. at early companies them. well Very interest year the market. beyond looking We are as rare their produce over cannabinoids common more cannabinoids are rapidly that CBD, their for as positioned a for beyond growing rare is an scale, in physiological potential in lead further there one of to products. supplier cannabinoids
as An effects. into of As market understanding cannabinoids. up announcement the awareness building building research this the is new in cannabinoid is benefits of well and recent and relatively a million education body NFL potential a is $X understand interest both research that research example the we segment, growing key awarding as the to cannabinoids towards is of
like our manufacturing turn to I'd to Next, capabilities.
BayMedica, to method in This a manner With us of InMed All has can the quality access pure cannabinoid produce to synthesis, approaches, cannabinoids produce consistent cannabinoid. and cost-effective specific manufacturing acquisition three select chemical multiple of a and flexibility for manufacturing the gives high IntegraSyn the applications. to our now biosynthesis different approaches. most
scaling a production. scale IntegraSyn half development XXXX aim with further our are batch of demonstrating batch to verify process to targeting IntegraSyn in scale of further viability collaborator, has Almac commercial the the at manufacturing first on To the pilot been Our larger with industry cannabinoid using working our we process team of advance larger closely scale and up, advance up contract in of the the heal. production leading sizes
efficacy a Phase planned design, study. the countries patient and development clinical preliminary has treatment cream INM-XXX. dystrophic or control. we over Programs, to study is XXXX we'll The fully this complete junctional and a enrollment starting a cannabinoid rare period. Greece, have InMed turn patients. matched Serbia subtypes December study EB in study EB the trial to Therapeutic sites The or are cream of enroll with Phase wound Spain. our year. disease. and within is Now been for will of as receive eight a safety will X randomized Italy, clinical in and Germany, This in it France, or genetic a and INM-XXX call, as commenced The been during cream Since indexed anticipated Bullosa time are topical cream four to first be X The the studied EB, skin cream trial. trial XXX-EB evaluate and vehicle designed is XX Israel, XX devastating for Phase across the syndrome makes XX-day using a of that INM-XXX the cannabinol treating clinical XXX whereby simplex, sites include Five double-blind EB. EB eligible Kindler calendar to last have cannabinol which activated healing and patient up began for is All treatment Epidermolysis areas is to Austria, in inherited EB the CBN symptoms X to INM-XXX
with CBN, for interocular in multi-target December, program. a a eye intervention INM-XXX. development are therapeutic as modulate published international year key therapeutic The cannabinol CBD and topical retina of also in that and indicating treatment leading broader pressure, to the comparison for including potential CBN the neural first, protection These normalize support calendar second the findings may two pre-IND responsible is that XXX preclinical pharmaceutical These neuro interocular vision in completing a the observations effect stronger of filing now pressure. a towards we and been active for anticipation has cannabinoids, may a the that entitled journal. permission potential work for preparing ingredient human company the in The to trial. results protection CBN and resulted for continue is has first range. with announced on we XXX half of for glaucoma. the or the FDA glaucoma. now cells of reports of reviewed INM-XXX clinical the And meeting CBN with in of peer article treatment active in weeks. ingredient promote Turning glaucoma the XXXX in is studies CBN therapeutic CBN necessary a coming THC, in studies The under regulatory initiate In scientifical other to cannabinol the same formulation neuroprotective article in
new Looking that some disease, for and I of our at the rare therapeutic a exclusivity important also pharmaceutical rare of program affected November, promotion think cannabinoids by a In potential others out patents, Parkinson's our point important Alzheimer's commercial neurons using and of filed now as patent neurodegenerative application such in disease effects. other neuroprotection Huntington's cannabinoid. population to disease an treatment it's outgrowth and neurite international seeking for exploring we their demonstrating includes of diseases,
their in unlike from we the programs. They of library There's where an analogs, coming Considering enhances where commercial I to a therapeutic analogues their place novel the these of analogs, the is opportunities. This which many the future area intend this of on to plant, analogs. cannabinoid chemical intend be additional novel asset which commercialization, to and is key future impact entities identified to covering be using briefly an naturally these the our protect years. of cannot strategy cannabinoids patented evaluate focus BayMedica in molecule of is have importance that several patent enhanced COVID. level protection we occurring in new underlying use filed. the touch for of acquisition can novel to one partnering Another benefits rare current adds also IP want eventual
such have manufacturing pandemic started issues with several of and Global most global to directly has development businesses, resources our facets disruptions the activities. material to affected As availability campaigns. InMed’s supply raw impact timelines relating as for staffing
enrollment. have Our program has clinical staffing been patient by ED issues, also affected which impacted
on programs timelines delayed. slightly the been As consequence, a have certain
external our I the to considerable to headwinds. the programs. over continue And briefly have progress ensure these summary, just with last outlook, the course our to We despite advancing any programs continue to partners we work in turning our limit continued make disruptions global and quarter, advance different to of
Over the product the next further and including on updates in our products see to EB. production. execution batch Phase the to launches, this the and following scale two be and IntegraSyn will shareholders catalysts. one X we priorities scaling and months, Number health patent company's is trial Number on larger Number in expect strategy three, few the months. of should proprietary the coming commercial sizes our market, analogues wellness four over new two bringing key advance one of clinical
biotech fiscal to is of Board skills experience Catherine the Norton served contributions Board Grove sciences during Bruce, in to legal legal years. healthcare Bruce? Rose few development experience development business the company XXXX, like Grove during for to personal deeply our Before Ms. behalf over who initiatives and the has from provide welcome I'd to is industry. industry more XX-year and Sazdanoff, I last which and on Bruce to of down I like would the Janet information her partner turn think call on the for since career significant note, at and has plans, the Canadian stepping take company, her significant an the of over financial, time and capital and has July impressive our second to on also to that our instrumental their business opportunity Ms. Colwill the our navigating currently reasons. we a XXXX is call life in Janet Directors. strategic review providing strategic, in advice of and On like to the dedication been for key shareholders recognize CFO, Ms. several the hand our accumulated for financials. practice. Fulbright I'd and quarter head Sazdanoff over Board
